Fig. 6: Combined IFNg and TNFa pathway activation is required to sensitize GSCs to TAK1 inhibition.
From: TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers
A CD44 surface staining of U3017MG treated for 3 days with indicated cytokines. B qPCR of ISGs, mesenchymal, or proneural marker gene expression after cytokine treatment. Error bar indicates mean +/− SD of 2 technical replicates. C, D Fold cell expansion of U3017MG cells pre-treated for 3 days with indicated cytokines followed by 4 days of DMSO or HS-276. E Effect of HS-276 treatment on fold cell expansion of 4 proneural GSCs after pre-treatment with indicated cytokines. F qPCR of ISG expression in U3013MG cells after 48 h of Ruxolitinib treatment. G Fold cell expansion and %Annexin V positive cells in U3013MG cells pre-treated with Ruxolitinib followed by 4 days of HS-276.
